Assay and Drug Development Technologies,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 12, 2025
Diabetes
management
necessitates
innovative
approaches
to
enhance
treatment
efficacy
and
patient
adherence.
The
study
aimed
develop
a
transdermal
patch
loaded
with
emodin,
hypothesized
provide
noninvasive
option
that
circumvents
complications
of
oral
administration.
To
optimize
the
formulation,
full
factorial
experimental
design
was
employed,
focusing
on
concentrations
hydroxypropyl
methylcellulose
K15
geraniol.
Compatibility
mechanical
characteristics
were
investigated
using
Fourier-transform
infrared
spectroscopy
differential
scanning
calorimetry.
patch's
drug
release
profile
assessed
via
in
vitro
studies,
while
its
stability
tested
under
accelerated
conditions.
antidiabetic
evaluated
diabetic
rats
an
vivo
model.
optimized
(batch
SF7)
released
94.57%
over
12
h.
Under
conditions,
showed
minor
decline
folding
endurance
from
396
±
1.50
369
2.63
folds
content
uniformity
98.70%
0.02%
98.14%
0.23%.
demonstrated
considerable
decrease
blood
glucose
levels
SF7-treated
245.83
3.25
mg/dL
120.86
4.24
h
(p-value
<
0.001),
comparable
standard
glibenclamide.
emodin-loaded
displayed
consistent
release,
maintained
stability,
significant
activity,
suggesting
it
is
promising
therapy
for
diabetes
management.
Assay and Drug Development Technologies,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 12, 2025
Diabetes
management
necessitates
innovative
approaches
to
enhance
treatment
efficacy
and
patient
adherence.
The
study
aimed
develop
a
transdermal
patch
loaded
with
emodin,
hypothesized
provide
noninvasive
option
that
circumvents
complications
of
oral
administration.
To
optimize
the
formulation,
full
factorial
experimental
design
was
employed,
focusing
on
concentrations
hydroxypropyl
methylcellulose
K15
geraniol.
Compatibility
mechanical
characteristics
were
investigated
using
Fourier-transform
infrared
spectroscopy
differential
scanning
calorimetry.
patch's
drug
release
profile
assessed
via
in
vitro
studies,
while
its
stability
tested
under
accelerated
conditions.
antidiabetic
evaluated
diabetic
rats
an
vivo
model.
optimized
(batch
SF7)
released
94.57%
over
12
h.
Under
conditions,
showed
minor
decline
folding
endurance
from
396
±
1.50
369
2.63
folds
content
uniformity
98.70%
0.02%
98.14%
0.23%.
demonstrated
considerable
decrease
blood
glucose
levels
SF7-treated
245.83
3.25
mg/dL
120.86
4.24
h
(p-value
<
0.001),
comparable
standard
glibenclamide.
emodin-loaded
displayed
consistent
release,
maintained
stability,
significant
activity,
suggesting
it
is
promising
therapy
for
diabetes
management.
